Digestive System Neoplasm

Meta-Analysis of 12 studies with 2,266 patients (54 % were KRAS wt). The pooled response rates (RR) for KRAS wild-type (wt) versus mutated (mut) patients were 54.8 and 48.3 %, respectively (OR 1.42, P… (full text at CIViC)

PMID 23828442 · Petrelli et al., 2013 · Open in CIViC

A preclinical study to investigate the efficacy of Binimetinib, Palbociclib and the combination on KRAS mutant colorectal cancer cell lines, cell line-derived and patient-derived xenografts. The com… (full text at CIViC)

PMID 27167191 · Lee et al., 2016 · Open in CIViC

SiRNA Screening in 37 KRAS Mutant colorectal cancer cell lines identified RAF1 and MEK Inhibition as synergistic, whereas MEK Inhibition alone led to quick resistance via upregulation of RAF-signallin… (full text at CIViC)

PMID 25199829 · Lamba et al., 2014 · Open in CIViC

This study shows that KRAS mutations such as G12D, G13D and KRAS amplification are frequent drivers of acquired resistance to cetuximab in colorectal cancers. KRAS mutant clones can be detected throug… (full text at CIViC)

PMID 22722830 · Misale et al., 2012 · Open in CIViC

A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xeno… (full text at CIViC)

PMID 22586653 · Bertotti et al., 2011 · Open in CIViC

This was a retrospective study of 605 patients with metastatic, chemotherapy refractory colorectal cancer treated with cetuximab + chemotherapy. Patients with KRAS mutant tumors (total [n = 253], codo… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

Combined treatment with dasatinib and cetuximab, but not either agent in monotherapy, had an antitumor efficacy in-vitro and in xenografts. These results were based on three KRAS mutant cell lines (LS… (full text at CIViC)

PMID 20956938 · Dunn et al., 2011 · Open in CIViC

NCCN guidelines indicate colorectal cancer patients with KRAS mutations should not be treated with the anti-EGFR therapies cetuximab or panitumumab.

PMID 28275037 · Benson et al., 2017 · Open in CIViC

A phase I study to determine the tolerability and pharmacokinetics of Selumetinib and Cetuximab with an expanded cohort in KRAS-mutant CRC. In the KRAS-mutant CRC dose expansion cohort 14 patients we… (full text at CIViC)

PMID 26666244 · Deming et al., 2016 · Open in CIViC

TLR9 agonist immunomodulatory oligonucleotide (IMO) led to inhibited survival of LS174T colorectal cancer and AsPC1 pancreatic cancer cell lines with KRAS mutations.

PMID 21890455 · Rosa et al., 2011 · Open in CIViC

Preclinical study in colorectal cancer xenografts. KRAS-G13D or KRAS-G12V mutations were introduced into KRAS-WT SW48 cell line. KRAS wild-type, but not KRAS mutant tumors were sensitive to proteasome… (full text at CIViC)

PMID 26709701 · Chattopadhyay et al., 2015 · Open in CIViC

Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655). All 25 patients with KRAS mutant colorectal cancer experienced PD. Median days on treatment was 57 (5-269).… (full text at CIViC)

PMID 24947927 · Zimmer et al., 2014 · Open in CIViC

A retrospective study of 2335 metastatic colorectal cancer (mCRC) patients, including 282 patients with type 2 diabetes mellitus (T2DM), examined the survival effects of metformin use in mCRC. Diabeti… (full text at CIViC)

PMID 32444490 · Xie et al., 2020 · Open in CIViC

Phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766. 4 patients with KRAS +/- PIK3CA mutant colorectal cancer. 3 with SD, 1 with PD.

PMID 23434733 · Weekes et al., 2013 · Open in CIViC

Phase 2 study in Asian patients with unresectable hepatocellular carcinoma. 70 patients received refametinib (BAY 86-9766) plus sorafenib as study treatment. A retrospective biomarker analysis was per… (full text at CIViC)

PMID 25294897 · Lim et al., 2014 · Open in CIViC

Inhibition of ERK in 11 KRAS mutant pancreatic cancer cell lines with SCH772984 was more effective than MEK Inhibition. Combined Treatment with PI3K Inhibitor AZD8186 was more effective than either ag… (full text at CIViC)

PMID 26725216 · Hayes et al., 2016 · Open in CIViC

Preclinial data from KRAS mutant colorectal cancer cell lines show syngergistic effect on cell viability and apoptosis in vitro and in vivo when MEK and IGF-IR are inhibited concomitantly. In other ce… (full text at CIViC)

PMID 21985784 · Ebi et al., 2011 · Open in CIViC

An shDNA Screen identified synergy betwenn ERBB3 Inhibition and MEK Inhibition in KRAS mutated cell lines. Dual EGFR/ERBB2 Inhibitors afatinib and dacomitinib and MEK Inhibition was synergistic in col… (full text at CIViC)

PMID 24685132 · Sun et al., 2014 · Open in CIViC

A 43-year-old female was diagnosed with an adenocarcinoma of the ascending colon and received 6-months of adjuvant chemotherapy. After 5 years of completion of adjuvant chemotherapy, the disease relap… (full text at CIViC)

PMID 19661358 · Palmirotta et al., 2009 · Open in CIViC

This was a retrospective study of 605 patients with metastatic, chemotherapy refractory colorectal cancer treated with cetuximab + chemotherapy. Patients harboring KRAS codon 61 mutations (n=13) had a… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

In irinotecan-resistant metastatic colorectal cancer patients who had been treated with cetuximab and irinotecan, KRAS mutations in codon 61 or 146 were associated with shorter progression-free surviv… (full text at CIViC)

PMID 19603018 · Loupakis et al., 2009 · Open in CIViC

In a retrospective study of 138 metastatic irinotecan-refractory, colorectal cancer patients, patients with a KRAS codon 61 or 146 mutation (8/68) treated with cetuximab plus chemotherapy were associa… (full text at CIViC)

PMID 19603018 · Loupakis et al., 2009 · Open in CIViC

In colorectal cancer patients, non-G12/G13 KRAS and NRAS mutations were associated with improved disease-free survival (n=186, P=0.006) compared to G12 and G13 KRAS mutations. None of the 12 Stage I-… (full text at CIViC)

PMID 20570890 · Janakiraman et al., 2010 · Open in CIViC

In irinotecan-resistant metastatic colorectal cancer patients who had been treated with cetuximab and irinotecan, KRAS mutations in codon 61 or 146 were associated with shorter progression-free surviv… (full text at CIViC)

PMID 19603018 · Loupakis et al., 2009 · Open in CIViC

In irinotecan-resistant metastatic colorectal cancer patients who had been treated with cetuximab and irinotecan, KRAS mutations in codon 61 or 146 were associated with shorter progression-free surviv… (full text at CIViC)

PMID 19603018 · Loupakis et al., 2009 · Open in CIViC

In a retrospective study of 138 metastatic irinotecan-refractory, colorectal cancer patients, patients with a KRAS codon 61 or 146 mutation (8/68) treated with cetuximab plus chemotherapy were associa… (full text at CIViC)

PMID 19603018 · Loupakis et al., 2009 · Open in CIViC

In irinotecan-resistant metastatic colorectal cancer patients who had been treated with cetuximab and irinotecan, KRAS mutations in codon 61 or 146 were associated with shorter progression-free surviv… (full text at CIViC)

PMID 19603018 · Loupakis et al., 2009 · Open in CIViC

In a retrospective study of 138 metastatic irinotecan-refractory, colorectal cancer patients, patients with a KRAS codon 61 or 146 mutation (8/68) treated with cetuximab plus chemotherapy were associa… (full text at CIViC)

PMID 19603018 · Loupakis et al., 2009 · Open in CIViC

In irinotecan-resistant metastatic colorectal cancer patients who had been treated with cetuximab and irinotecan, KRAS mutations in codon 61 or 146 were associated with shorter progression-free surviv… (full text at CIViC)

PMID 19603018 · Loupakis et al., 2009 · Open in CIViC

In a retrospective study of 138 metastatic irinotecan-refractory, colorectal cancer patients, patients with a KRAS codon 61 or 146 mutation (8/68) treated with cetuximab plus chemotherapy were associa… (full text at CIViC)

PMID 19603018 · Loupakis et al., 2009 · Open in CIViC

In irinotecan-resistant metastatic colorectal cancer patients who had been treated with cetuximab and irinotecan, KRAS mutations in codon 61 or 146 were associated with shorter progression-free surviv… (full text at CIViC)

PMID 19603018 · Loupakis et al., 2009 · Open in CIViC

In a retrospective study of 138 metastatic irinotecan-refractory, colorectal cancer patients, patients with a KRAS codon 61 or 146 mutation (8/68) treated with cetuximab plus chemotherapy were associa… (full text at CIViC)

PMID 19603018 · Loupakis et al., 2009 · Open in CIViC

In irinotecan-resistant metastatic colorectal cancer patients who had been treated with cetuximab and irinotecan, KRAS mutations in codon 61 or 146 were associated with shorter progression-free surviv… (full text at CIViC)

PMID 19603018 · Loupakis et al., 2009 · Open in CIViC

In a retrospective study of 138 metastatic irinotecan-refractory, colorectal cancer patients, patients with a KRAS codon 61 or 146 mutation (8/68) treated with cetuximab plus chemotherapy were associa… (full text at CIViC)

PMID 19603018 · Loupakis et al., 2009 · Open in CIViC

The authors demonstrated that in contrast to the K-RasG12D or K-RasG12V mouse models, mice that express the K-RasV14I mutation at postnatal stages, either in all cells or only in the lungs, did not de… (full text at CIViC)

PMID 27174785 · Hernández-Porras et al., 2016 · Open in CIViC

In this open-label, randomized, controlled, phase III trial, 1,198 patients with histologically confirmed adenocarcinoma of the colon or rectum and immunohistochemical evidence of tumour EGFR expressi… (full text at CIViC)

PMID 19339720 · Van Cutsem et al., 2009 · Open in CIViC

The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC)

PMID 21641636 · Maughan et al., 2011 · Open in CIViC